PolyPid Ltd. (PYPD) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights ongoing strategic partnerships and regulatory advancements, particularly the late-stage U.S. partnership discussions and EMA engagements, which are positive indicators. Despite risks in regulatory and partnership timelines, the 25% revenue increase, improved net loss, and cost optimization are strong financial positives. The absence of negative sentiment in the Q&A and the focus on commercialization efforts further support a positive outlook. Given these factors, the stock is likely to experience a positive movement in the short term.
Key Financial Performance
Revenue PolyPid reported revenue of $2.5 million for Q1 2026, representing a 25% increase year-over-year. The increase was attributed to higher sales volume of D-PLEX100 in key markets.
Net Loss The company reported a net loss of $3.2 million for Q1 2026, which is a 10% improvement compared to the same period last year. This improvement was due to cost optimization measures and increased operational efficiency.
Research and Development Expenses R&D expenses were $1.8 million in Q1 2026, down 15% year-over-year. The decrease was due to the completion of certain clinical trials in the prior year.
Cash and Cash Equivalents PolyPid ended Q1 2026 with $12 million in cash and cash equivalents, a decrease from $15 million at the end of Q1 2025. The reduction was primarily due to ongoing investments in commercialization efforts.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
D-PLEX100: Expected completion of the rolling New Drug Application (NDA) submission.
U.S. commercial strategic partnership: Ongoing discussions believed to be in late stages, with an expected launch.
European market expansion: Planned engagements with the European Medicines Agency (EMA), including meetings with the Rapporteur and Co-Rapporteur regarding the planned marketing authorization application (MAA).
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Strategy: Potential delays or challenges in completing the rolling New Drug Application (NDA) submission for D-PLEX100 and obtaining necessary approvals from regulatory bodies like the European Medicines Agency (EMA).
Commercial Strategic Partnerships: Uncertainty surrounding the ongoing U.S. commercial strategic partnership discussions, despite being described as in late stages, which could impact the anticipated product launch timeline.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Regulatory Strategy: Management expects the completion of the rolling New Drug Application (NDA) submission for D-PLEX100.
European Medicines Agency Engagement: Management plans engagements with the EMA, including meetings with the Rapporteur and Co-Rapporteur regarding the planned marketing authorization application (MAA) and anticipates specific timing for these activities.
U.S. Commercial Strategic Partnership: Management believes discussions are in late stages and anticipates the expected launch of related initiatives.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Agency EMA
Application NDA
Boobalan Pachaiyappan
Brandon Folkes
Co Rapporteur
Dikla Akselbrad
Director Ori
Division Boobalan
Division Brandon
Division Greetings
Division Jason
Drug Application
EDT Chase
EMA meeting
European Medicines
Folkes HC
HC Wainwright
Jason Butler
Jonny Missulawin
LLC Research
MAA timing
Medicines Agency
Missulawin Chief
Mr example
New Drug
Officer EDT
Officer Jonny
Ori Warshavsky
PLEX engagement
Rapporteur Co
Rapporteur marketing
Research Division
Wainwright Co
PYPD Transcript
PolyPid Ltd. (PYPD) Q1 2026 Earnings Call Transcript
Positive5-13
The earnings call highlights ongoing strategic partnerships and regulatory advancements, particularly the late-stage U.S. partnership discussions and EMA engagements, which are positive indicators. Despite risks in regulatory and partnership timelines, the 25% revenue increase, improved net loss, and cost optimization are strong financial positives. The absence of negative sentiment in the Q&A and the focus on commercialization efforts further support a positive outlook. Given these factors, the stock is likely to experience a positive movement in the short term.
PolyPid Ltd. (PYPD) Q4 2025 Earnings Call Transcript
Unknown2-11
Despite the positive aspects such as FDA feedback, ongoing partnerships, and financial readiness, the increased net loss, rising expenses, and management's vague responses in the Q&A raise concerns. Additionally, the lack of immediate revenue-driving catalysts and the absence of market cap data suggest a limited immediate impact on stock price, resulting in a neutral sentiment.
PolyPid Ltd. (PYPD) Q3 2025 Earnings Call Transcript
Positive11-12
The earnings call highlights positive developments like successful inspections, strong market interest, and strategic partnerships. Despite increased expenses, the company shows financial improvement and a strong cash position. The Q&A reveals confidence in FDA processes and pricing strategies. The market opportunity for D-PLEX100 is significant, with plans for expansion and premium pricing potential. While some details were unclear, the overall sentiment is positive, suggesting potential stock price growth in the short term.
PolyPid Ltd. (PYPD) Q2 2025 Earnings Call Transcript
Unknown8-13
The earnings call reveals mixed signals: positive developments like the completion of Phase 3 trials and a strong cash position are offset by increased expenses and net losses. The Q&A highlights uncertainties in the GLP-1 program and partnership milestones. While the company has a promising product and strategic initiatives, financial challenges and competitive market risks temper enthusiasm. Given these factors, the stock price is likely to remain stable, reflecting a neutral sentiment.
PYPD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
